English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In an attempt to create novel methods to reduce the transmission of SARS-CoV-2 and influenza viruses, fabric material was treated with Viruferrin™ and tested for its inactivating properties against the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A viruses. Inactivating properties were evaluated by comparing Viruferrin-treated and cotton control fabric material with and without the application of saliva at various time points after virus exposure. A statistically significant ( p &lt; 0.0001) decrease in the number of infectious virus particles exposed to Viruferrin-treated fabric when compared with the cotton control for both SARS-CoV-2 and influenza A viruses was observed. For both SARS-CoV-2 and influenza A, Viruferrin-treated fabrics experienced a &gt;99% virus reduction without saliva after five minutes of contact when compared to the positive control at time point 0. Furthermore, the reusability of the Viruferrin treated fabric was demonstrated by stability for up to 10 washes. The level of anti-viral (SARS-CoV-2) activity remained constant from 5 to 10 washes and demonstrated a significant difference ( p &lt; 0.0001) from the unwashed untreated material. Applications for this treated fabric are far reaching, as a biological face covering offers not only a unique 2-way protection but also is unlikely to cause onward touch transmission.

Biological Cloth Face Coverings—The Reduction of SARS-CoV-2 and Influenza (H1N1) Infectivity by Viruferrin™ Treatment